Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

---

Obesity hypoventilation syndrome: current status and future directions for optimizing care of a complex and diverse condition (a narrative review)

Sleep Medicine, Journal Year: 2025, Volume and Issue: unknown, P. 106491 - 106491

Published: March 1, 2025

Language: Английский

---

Teratogenic risks of treated and untreated maternal obesity

Seminars in Perinatology, Journal Year: 2025, Volume and Issue: unknown, P. 152081 - 152081

Published: April 1, 2025

Language: Английский

---